Last reviewed · How we verify
Systemic dupilumab
At a glance
| Generic name | Systemic dupilumab |
|---|---|
| Also known as | DUPIXENT |
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
- Registry for Systemic Eczema Treatments
- Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
- Microbiome in Atopic Dermatitis Under Systemic Therapy
- Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |